William H. Lewis, J.D.
President and Chief Executive Officer
Will joined Insmed in 2012 as President and Chief Executive Officer and as a member of the Board of Directors. Will is the former Co-Founder, President, and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), and previously spent more than 10 years working in investment banking in the U.S. and Europe. He also previously worked for the U.S. government. Will holds a Bachelor of Arts degree cum laude from Oberlin College as well as a Master of Business Administration and a Juris Doctor with Honors from Case Western Reserve University.
Chief Financial Officer
Paolo joined Insmed in June 2017. He brings over 20 years of experience in the biotechnology and pharmaceutical sector, most recently serving as Vice President and Chief Financial and Administrative Officer of Novartis Pharmaceuticals Corporation. In addition, Paolo was a member of Novartis’s Pharma Executive Committee, Commercial Leadership Team, Corporate Compliance Committee, Global Pharma Finance Leadership Team, and Global Country CFO Team. He joined Novartis in 2006 as Head of Finance Region Europe, Oncology, and held several positions of increasing responsibility, including serving as Managing Director and CFO of Novartis Japan. Prior to joining Novartis, Paolo held various financial positions with Bristol-Myers Squibb. His career began in consumer goods with Unilever NV and Johnson & Johnson. He holds a degree in business and managerial economics from Rome’s La Sapienza University and a degree in accounting from Duca degli Abruzzi Roma.
Paul Streck, M.D.
Chief Medical Officer
Paul joined Insmed in June 2017, bringing over 25 years of clinical development, management, and leadership expertise. Most recently, Paul served as Vice President, Global Medical Specialty Franchise, Immuno-inflammation at GlaxoSmithKline where he was responsible for portfolio strategy, including drug launch, life cycle management, post-registration clinical strategy, and health economics. Previously, he held various positions in clinical development, medical affairs, and commercial with Shire and Amgen. He also practiced in the Jefferson Health System at Thomas Jefferson University. Paul received his medical degree from Jefferson Medical College and was a resident in oral and maxillofacial surgery at Thomas Jefferson University Hospital. He also holds a Doctor of Dental Medicine degree from Temple University School of Dentistry, a Master of Business Administration from the Duke University Fuqua School of Business, and board certification in oral and maxillofacial surgery from the American Board of Oral and Maxillofacial Surgery.
Chief Commercial Officer
Roger joined Insmed in September of 2016. Prior to Insmed, Roger held various leadership roles with Shire from 2005 to 2016. During his time as senior vice president of its gastrointestinal and internal medicine business unit, Roger oversaw global commercial P&L across six specialty and two rare disease brands within his BU. Previously, he served as Shire’s gastrointestinal business unit leader, responsible for building a leading GI specialty business. Before Shire, Roger worked at AstraZeneca for 11 years in a variety of commercial positions, including marketing director for the US launch of Nexium®, a medicine for the treatment of gastroesophageal reflux disease (GERD), and the global brand director for Symbicort®, a medicine for the treatment of asthma and chronic obstructive pulmonary disease. Prior to AstraZeneca, Roger spent three years at Accenture. Roger holds a Master of Business Administration from The Wharton School at the University of Pennsylvania and a Bachelor of Arts in English and Economics from Bucknell University.
Christine Pellizzari, J.D.
Chief Legal Officer
Christine joined Insmed in 2013 as General Counsel & Corporate Secretary, bringing over 20 years of leadership in the global biopharmaceutical industry. Prior to Insmed, Christine served as Executive Vice President, General Counsel and Secretary of Aegerion Pharmaceuticals, Inc., where she oversaw all legal aspects of the company’s successful IPO and secondary public offering and served as a member of the Executive Management Committee. Prior to Aegerion, Christine served as Senior Vice President, General Counsel and Secretary of Dendrite International, Inc., a publicly traded company that provided sales effectiveness, promotional and compliance solutions to the pharmaceutical industry. As a member of the company’s management team, she led many critical initiatives including the sale of the company to Cegedim S.A. in 2007. Christine joined Dendrite from the law firm of Wilentz, Goldman & Spitzer where she specialized in health care transactions and related regulatory matters. She previously served as law clerk to the Honorable Reginald Stanton, Assignment Judge for the Superior Court of New Jersey. Christine received her Bachelor of Arts, cum laude, from the University of Massachusetts, Amherst and her Juris Doctor degree from the University of Colorado, Boulder.
Chief People Strategy Officer
Nicole joined Insmed in October 2012. She brings more than 25 years of experience in Human Resources, organizational development, corporate operations, and building life science organizations. Prior to Insmed, Nicole served as Senior Vice President, Administration and Human Resources, for Amicus Therapeutics where she was responsible for the human resources, facilities, and IT functions. At Amicus, Nicole was responsible for the organizational growth and development from its earliest stages to a late-stage clinical company. During this time, she focused on developing a culture of excellence to support that growth. Prior to Amicus, Nicole served as Senior Director, Human Resources, for three portfolio companies of Flagship Ventures, a venture capital firm. She has also held HR leadership positions with Oak Industries and EMC Corporation. Nicole received her Bachelor of Arts from the University of Rochester and her Master of Business Administration from Boston University.
Eugene Sullivan, M.D.
Chief Product Strategy Officer
Gene joined Insmed in March 2015 as Chief Medical and Scientific Officer and in June 2017 was appointed to the newly created role of Chief Product Strategy Officer. Gene has more than 20 years of experience with a focus on pulmonary and orphan diseases. He is a medical doctor trained in internal medicine, pulmonary medicine, and critical care medicine and practiced at the Cleveland Clinic from 1995 to 1999. From 1999 through 2006, Gene held several positions at the U.S. Food and Drug Administration, including Deputy Director of the Division of Pulmonary and Allergy Products. From 2007 through 2012, Gene was the Chief Medical Officer of United Therapeutics. In recent years, Gene was Vice President, Global Regulatory Affairs at AstraZeneca and consulted to companies, including Insmed, on clinical drug development and strategic regulatory matters. Gene graduated summa cum laude from the University of Maryland with a Bachelor of Science degree. He earned his medical degree from the University of Maryland, School of Medicine and conducted his internship and residency in Internal Medicine at the Medical College of Virginia. Gene completed his fellowship training in Pulmonary and Critical Care Medicine at the University of Colorado Health Sciences Center and received a Master of Pulmonary Vascular Disease from the University of Bologna in Italy.
John Soriano, J.D.
Chief Compliance Officer
John joined Insmed in January 2018, bringing over 30 years of experience in legal and compliance leadership roles. Most recently, John was Senior Vice President and Chief Compliance Officer at Celgene where he oversaw the Global Compliance Program. Before Celgene, John was Vice President-Compliance and Deputy General Counsel at Ingersoll-Rand Company. He has also worked as a litigation attorney at Becton Dickinson, Johnson & Johnson, and Simpson Thacher & Bartlett. He received his undergraduate degree from Princeton’s Woodrow Wilson School of Public and International Affairs and his Juris Doctor degree from Harvard Law School.
Walter Perkins, PhD
Chief Technology Officer
Walter joined Insmed in December 2010 in connection with the business combination between Insmed and Transave. Prior to this, Walter joined Transave in 2002 and served as Chief Technology Officer. Walter has over 25 years’ experience utilizing nanoparticle drug delivery systems for multiple routes of administration including inhalation and has authored 80 scientific publications and U.S. patent applications. Prior to Transave, Walter spent 15 years with The Liposome Company (later a part of Elan Drug Delivery), where he was involved in the design of several lipid-based drug delivery systems, including an artificial lung surfactant formulation, and helped in the characterization, development, and launch of the company’s two commercial products Abelcet® and Myocet®. As part of Elan’s Drug Delivery Division, Walter played a lead role in the implementation of liposome technology in both inter-divisional projects and corporate partnerships. Walter received his bachelor and doctoral degrees in Biophysical Chemistry from the University of Virginia, where he studied liposomes as model membrane systems.
Wade King, M.D.
Senior Vice President, Corporate Development & Strategy
Wade joined Insmed in March 2016, bringing a unique scientific and financial background to the company that includes numerous leadership roles in business development, finance, management, and strategy at healthcare and investment companies. Previously, he was Head of Business Development and Finance for NeoMend, prior to the company’s acquisition. Wade began his career as a board-certified anesthesiologist before joining the investment sector where he earned national recognition as a healthcare analyst. He holds a Bachelor of Arts degree, cum laude, from Princeton University; Doctor of Medicine and Master of Public Health degrees from University of North Carolina, Chapel Hill; and a Master of Science in Management degree from Stanford Graduate School of Business.